Zur Durchführbarkeit von spezifischer zytostatischer Therapie bei Patienten mit malignen Erkrankungen in höherem Lebensalter

Retrospektive unizentrische Analyse zur Toxizität und Effektivität einer Hochdosischemotherapie (BEAM) mit autologer Stammzelltransplantation bei Patienten mit rezidiviertem Lymphom im Alter über 60 Jahre

Feasability of cytostatic therapy in elderly patients with malignant diseases

Retrospective single center analysis of toxicity and efficacy in high-dose chemotherapy (BEAM) and autologous stem cell transplantation in elderly patients (> 60 years) with relapsed lymphoma

by Nicola Susanne Götz
Doctoral thesis
Date of Examination:2014-01-15
Date of issue:2014-01-15
Advisor:Dr. Björn Chapuy
Referee:Prof. Dr. Gerald Wulf
Referee:PD Dr. Joachim Riggert
Persistent Address: http://dx.doi.org/10.53846/goediss-4316

 

 

Files in this item

Name:Götz2014(1).pdf
Size:1.20Mb
Format:PDF
Name:Nicolas Dissertation - Version nach doktorpr...pdf
Size:1.01Mb
Format:PDF

The following license files are associated with this item:

Abstract

English

High-dose chemotherapy followed by autologous haematopoietic stem cell transplantation (ASCT) is standard therapy for relapsed or primary refractory aggressive Non-Hodgkin lymphoma (NHL). Although the incidence of aggressive lymphoma with high risk features increases with age, the applicability of high-dose chemotherapy in patients aged > 60 is an issue due to concerns on toxicity and co-morbidity. We here present a retrospective single centre experience with high-dose chemotherapy using the BEAM preparative regiment followed by autologous HSC transplantation in elderly patients with relapsed lymphoma. Between 3/1994 and 6/2006, 79 consecutive patients received BEAM and ASCT in our institution. Of those, 20 patients were older than 60 years (range 60 to 69 years), and 59 patients younger than 60 years at commencement of therapy. A second control group of 10 patients younger than 60 years received TBI/Cy. Comparing hematopoietic recovery in theses age groups, the median days of neutropenia and thrombocytopenia in younger vs. elderly were 7.5 vs. 7 days, and 4 vs. 3.5 days, respectively. The necessity for erythrocyte transfusions was, however, significantly higher in elderly patients (43% WHO grad III/IV toxicity in younger vs. 70% in elderly patients). As for non-hematological toxicity, the incidences of severe infections and stomatitis, as well as diarrhoea and dysarrhythmias were higher in the elderly patients. All further parameters of non-hematological toxicity including treatment related mortality were equally distributed. In conclusion, high-dose chemotherapy with BEAM and ASCT is a feasible option for selected patients older 60 years. Algorithms to guide therapeutic decisions in elderly patients with relapsed aggressive lymphoma are to be developed.
Keywords: high-dose chemotherapy; lymphoma; stem cell transplantation; elderly patients
Schlagwörter: maligne Lymphome; Stammzelltransplantation; Hochdosischemotherapie; Patienten > 60 Jahre; Toxizitäten
 
Statistik